Nanoparticle Bioconjugation Scientist

Early is Good (EIG) is developing non-invasive, multi-omic based tests to improve the accuracy and accessibility of cancer detection. Our Multi-omic Integration Platform combines DNA, RNA, protein, and metabolite detection into one test, providing earlier and more precise cancer diagnosis.

We're hiring a Nanoparticle Bioconjugation Scientist with extensive experience in nanoparticle science, bioconjugation, surface chemistry, and assay development. You'll be a key player in designing, developing, and scaling nanoparticle-based assays and surface modification strategies for high-sensitivity diagnostics. You'll also work closely with our cross-functional team to push the limits of cancer diagnostics.

Your responsibilities will include:

• Design and develop nanoparticle conjugation methods for high-sensitivity assays
• Optimize protocols for nanoparticle functionalization, including iron oxide and colloidal gold
• Implement bioconjugation strategies like PEGylation, biotinylation, and covalent coupling with antibodies, antigens, nucleic acids, and small molecules
• Troubleshoot and improve bioconjugation processes to enhance stability, sensitivity, and specificity
• Collaborate with product development and scale-up teams to ensure consistent performance in nanoparticle assays
• Maintain detailed experiment records, contribute to reports, and share insights with the team

Must have:

• Ph.D/MsC. in Biochemistry, Chemistry, Materials Science, or a related field, focused on nanoparticle bioconjugation with 5+ years of industrial experience
• Strong expertise in nanoparticle surface modification and functionalization
• Hands-on experience with various conjugation chemistries, including thiol, amine, acid, azide, and other click chemistries
• Proven success in developing particle-based immunoassays, like ELISA and lateral flow
• Solid background in analytical methods for characterizing nanoparticles
• Ability to work effectively as part of a cross-functional team

Nice to have:

• Experience with scaling nanoparticle products for FDA-regulated markets.
• Background in developing in vitro diagnostic assays, especially in oncology applications